2-(3-ethynyl-5-(pyridin-3-yloxy)phenyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide

ID: ALA5286838

Max Phase: Preclinical

Molecular Formula: C20H14N2O3S

Molecular Weight: 362.41

Names and Identifiers

Canonical SMILES:  C#Cc1cc(Oc2cccnc2)cc(N2Cc3ccccc3S2(=O)=O)c1

Standard InChI:  InChI=1S/C20H14N2O3S/c1-2-15-10-17(12-19(11-15)25-18-7-5-9-21-13-18)22-14-16-6-3-4-8-20(16)26(22,23)24/h1,3-13H,14H2

Standard InChI Key:  XIOGALHZYZVCEI-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 26 29  0  0  0  0  0  0  0  0999 V2000
   -0.1960   -1.6773    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1960   -0.8523    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9127   -0.4441    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9127    0.3847    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6276    0.7974    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3425    0.3847    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0600    0.7990    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7717    0.3826    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7717   -0.4383    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0554   -0.8509    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3425   -0.4403    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1978    0.7971    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5143    0.3851    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2293    0.7978    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.9830    0.4622    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    2.5658   -0.1217    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.7690   -0.3360    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.5351    1.0754    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3638    1.0754    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7717    1.7923    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3597    2.5023    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5344    2.5023    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1226    1.7900    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3155    1.6184    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5143   -0.4404    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1960   -2.5023    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  0
  3  2  2  0
  4  3  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11  6  2  0
 12  4  2  0
 13 12  1  0
 13 14  1  0
 15 14  1  0
 15 16  2  0
 15 17  2  0
 18 15  1  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 23 22  1  0
 23 18  2  0
 24 23  1  0
 24 14  1  0
 25 13  2  0
  2 25  1  0
  1 26  3  0
M  END

Alternative Forms

1. Parent:

   

   ALA5286838

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 362.41

Molecular Weight (Monoisotopic): 362.0725

AlogP: 3.56

#Rotatable Bonds: 3

Polar Surface Area: 59.50

Molecular Species: NEUTRAL

HBA: 4

HBD: ┄

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): ┄

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 11.39

CX Basic pKa: 4.61

CX LogP: 2.87

CX LogD: 2.87

Aromatic Rings: 3

Heavy Atoms: 26

QED Weighted: 0.67

Np Likeness Score: -1.41

References

1. Carullo G, Mazzotta S, Vega-Holm M, Iglesias-Guerra F, Vega-Pérez JM, Aiello F, Brizzi A..  (2021)  GPR120/FFAR4 Pharmacology: Focus on Agonists in Type 2 Diabetes Mellitus Drug Discovery.,  64  (8.0): [PMID:33843223] [10.1021/acs.jmedchem.0c01002]

Source

Source(1):

• Scientific Literature